Current NattoPharma CEO appointed to Interim CEO of PharmaCo. Current CFO to take on additional role as Interim CEO of NattoPharma. Additional resources and capabilities are added to NattoPharma sales and supply chain functions.

 

Oslo, Norway (8 February 2018) – Following the PharmaCo spin-off, Daniel Rosenbaum, current CEO of NattoPharma will be seconded to PharmaCo in order to assure an effective transition and immediate start-up of PharmaCo critical operations. During this period Mr. Rosenbaum will serve as the Interim CEO while the newly formed Board of Directors of PharmaCo AS works to select and appoint a permanent management team.

The NattoPharma board is highly optimistic about the extraordinary potential of pharmaceutical therapeutic applications of vitamin K2-MK7. It is therefore a priority to assure the continued momentum and seamless transition during this initial period. During this time Mr. Rosenbaum will be fully dedicated to the continued development and implementation of the pharmaceutical strategy, together with the newly appointed PharmaCo board.

Of equal importance is for NattoPharma to continue with its growth and performance gains. Thus, during this period, the Board of Directors of NattoPharma has further appointed Kjetil Ramsøy, current NattoPharma CFO, as Interim CEO. Mr. Ramsøy will also continue to act as CFO during this period.

With PharmaCo now fully responsible for driving the pharmaceutical initiative, Nattopharma will focus on sales growth and commercialization within the nutraceutical segment. To strengthen its commercial reach, NattoPharma is in the process of expanding its sales team with 2 to 4 people in Europe and Asia. More information will be announced in the next few weeks. To assure continuity in the company’s ability to drive its expansion plans, NattoPharma will also increase its global supply chain capabilities. In line with this priority, Mr. Peter Stahl, an expert in the areas of operations management, has joined the NattoPharma team for an extended engagement as Interim COO.

There are now two, highly focused entities with the potential to drive significant value creation in their respective areas. NattoPharma will focus in the dietary supplement and nutraceutical segments, where it continues to lead with its flagship MenaQ7 vitamin K2, selectively adding new, scientifically validated ingredients to its portfolio. PharmaCo AS will now be fully dedicated to taking the pharmaceutical initiative to the next level as it begins the next phase of clinical development and regulatory approvals.

# # #

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:

Kjetil Ramsøy
CEO/CFO, NattoPharma
E-mail: kjetil.ramsoy@nattopharma.com

Daniel Rosenbaum
CEO, PharmaCo
Email: daniel.rosenbaum@nattopharma.com